New Strategies in Overcoming Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

The management of non-small cell lung cancer (NSCLC) has been transformed by the observation that lung adenocarcinomas harboring mutations in EGFR are uniquely sensitive to EGFR tyrosine kinase inhibitors (TKIs). In these patients, acquired resistance to EGFR-TKI develops after a median of 10-14 mon...

Full description

Saved in:
Bibliographic Details
Main Authors: Oxnard, Geoffrey R., Arcila, Maria E., Chmielecki, Juliann, Ladanyi, Marc, Miller, Vincent A., Pao, William
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3166976/
https://ncbi.nlm.nih.gov/pubmed/21775534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2571
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items